Dysport is now approved to treat ULS in adults to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. The company said
About 360 patients with DES will be included in the multicenter, randomized, double-masked Phase IIb/III trial, which will evaluate the efficacy and superiority of GBT-201 compared to placebo.
Amoun is a major company in Egypt’s pharmaceutical sector and owns brands in therapeutic areas such as anti-hypertensives, broad-spectrum antibiotics and anti-diarrheals. Currently, Amoun expects to reach EGP1.75bn
C2N-8E12 is a humanized antibody that targets the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer’s disease (AD).
AstraZeneca has completed the divestment of non-US global rights of its gastroenterology drug Entocort to Tillotts Pharma (Tillotts), part of the Zeria Group, for $215m. Entocort (budesonide) is
The FDA granted orphan drug status for Anisina under the US Orphan Drug Act following a review by the agency of a package of pre-clinical data from preclinical
The company said that its bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. Additionally, Hospira intends to launch a
The agreement expands upon the strategic manufacturing alliance entered in December 2012 concerning the North Carolina facility. As part of the new deal, Eisai will transfer to Biogen
Epiduo Forte Gel is the first combination of retinoid, adapalene and benzoyl peroxide, developed for the moderate to severe acne population. Acne is the most common skin condition
The open-label, single-arm, multicenter trial showed blinatumomab monotherapy induced a complete remission or complete remission with partial hematological recovery within two cycles of treatment in a clinically meaningful
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.